Heaton Alan, Martin Steve, Brelje Tim
Pharmacoeconomic and Outcomes Research Department, Prime Therapeutics Inc., Eagan, Minnesota, USA.
Manag Care Interface. 2003 Jul;16(7):23-7.
This study was undertaken to determine the incidence and economic cost of hypoglycemia in patients with diabetes taking insulin in a large mid-western health plan. Analysis of claims data identified 7,659 members with a diagnostic code for either type 1 or type 2 diabetes during a seven-year interval from 1992 to 1998. A total of 2,118 were prescribed some type of insulin regimen. During the six years of follow-up, more than 16% of insulin-treated patients experienced hypoglycemia profound enough to warrant medical attention. The mean cost per episode was $1,186 (range, $181-$4,924) or $7.04 per patient per month. Although the financial burden is smaller than that of late complications of diabetes, hypoglycemia associated with insulin therapy is associated with significant costs to the health care system.
本研究旨在确定美国中西部一个大型健康计划中接受胰岛素治疗的糖尿病患者低血糖的发生率和经济成本。对索赔数据的分析确定了在1992年至1998年的七年期间，有7659名成员患有1型或2型糖尿病的诊断代码。共有2118人采用了某种胰岛素治疗方案。在六年的随访中，超过16%接受胰岛素治疗的患者经历了严重到需要医疗关注的低血糖。每次发作的平均费用为1186美元（范围为181美元至4924美元），即每位患者每月7.04美元。虽然经济负担小于糖尿病晚期并发症，但与胰岛素治疗相关的低血糖会给医疗保健系统带来巨大成本。
